We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+3.81%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$20.3B
AUM Growth
+$699M
(+3.6%)
Cap. Flow
+$215M
Cap. Flow
% of AUM
1.06%
Top 10 Holdings %
Top 10 Hldgs %
24.84%
Holding
742
New
18
Increased
309
Reduced
385
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$82.6M |
| 2 |
Alamos Gold
AGI
|
+$61.6M |
| 3 |
Halliburton
HAL
|
+$53.6M |
| 4 |
Gold Fields
GFI
|
+$39.9M |
| 5 |
Bunge Global
BG
|
+$39.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$112M |
| 2 |
B
Barrick Mining
B
|
+$101M |
| 3 |
Franco-Nevada
FNV
|
+$83.9M |
| 4 |
GG
Goldcorp Inc
GG
|
+$63.3M |
| 5 |
Freeport-McMoran
FCX
|
+$58.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 50.07% |
| 2 | Energy | 18.24% |
| 3 | Healthcare | 7.4% |
| 4 | Technology | 5.44% |
| 5 | Consumer Discretionary | 2.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Bausch Health
BHC
$1.65B
| $14.3M | 0.07% |
689,136
-7,525
| -1% | -$119K |
|
202
Qorvo
QRVO
$7.63B
| $14.3M | 0.07% |
214,003
+57,966
| +37% | +$4.22M |
|
203
Viatris
VTRS
$20.1B
| $14.1M | 0.07% |
332,533
-56,614
| -15% | -$2.16M |
|
|
GRFS
204
Grifois
GRFS
$5.16B
| $14.1M | 0.07% |
613,577
-304,099
| -33% | -$6.75M |
|
205
Toro Company
TTC
$8.93B
| $14M | 0.07% |
214,199
+2,302
| +1% | +$146K |
|
|
NVO
206
Novo Nordisk
NVO
$216B
| $13.9M | 0.07% |
516,524
-57,822
| -10% | -$1.47M |
|
207
AbbVie
ABBV
$458B
| $13.8M | 0.07% |
142,782
-36,237
| -20% | -$3.42M |
|
208
GSK
GSK
$103B
| $13.8M | 0.07% |
311,105
+36,336
| +13% | +$1.68M |
|
|
DCUD
209
DELISTED
Dominion Energy, Inc 2016 Series A Corporate Units
DCUD
| $13.7M | 0.07% |
264,956
+24,532
| +10% | +$1.27M |
|
210
Novartis
NVS
$295B
| $13.6M | 0.07% |
180,605
-2,230
| -1% | -$168K |
|
211
Vale
VALE
$62.9B
| $13.4M | 0.07% |
1,099,349
-264,359
| -19% | -$2.81M |
|
212
Sanofi
SNY
$104B
| $13.4M | 0.07% |
312,200
+34,208
| +12% | +$1.58M |
|
213
Johnson & Johnson
JNJ
$635B
| $13.3M | 0.07% |
95,341
-9,803
| -9% | -$1.37M |
|
|
ANTX
214
DELISTED
Anthem, Inc.
ANTX
| $13.2M | 0.07% |
236,569
+21,903
| +10% | +$1.19M |
|
215
FS KKR Capital
FSK
$2.98B
| $12.8M | 0.06% |
434,385
+20,015
| +5% | +$643K |
|
|
CAVM
216
DELISTED
Cavium, Inc.
CAVM
| $12.8M | 0.06% |
152,311
+48,555
| +47% | +$3.76M |
|
217
Ternium
TX
$9.29B
| $12.4M | 0.06% |
394,079
-102,281
| -21% | -$3.06M |
|
|
VEDL
218
DELISTED
Vedanta Limited American Depostary Shares (Each representing four equity shares)
VEDL
| $12.4M | 0.06% |
593,645
-154,585
| -21% | -$3.03M |
|
|
MSCC
219
DELISTED
Microsemi Corp
MSCC
| $12.3M | 0.06% |
237,381
+57,357
| +32% | +$3.01M |
|
220
AGNC Investment
AGNC
$12.3B
| $12.1M | 0.06% |
600,086
+110,665
| +23% | +$2.28M |
|
221
United Therapeutics
UTHR
$26.3B
| $11.7M | 0.06% |
79,383
-43,717
| -36% | -$5.56M |
|
222
Jazz Pharmaceuticals
JAZZ
$15.9B
| $11.7M | 0.06% |
86,919
+3,709
| +4% | +$514K |
|
|
KMI.PRA
223
DELISTED
Kinder Morgan, Inc.
KMI.PRA
| $11.5M | 0.06% |
302,808
+28,036
| +10% | +$1.06M |
|
224
Alnylam Pharmaceuticals
ALNY
$36.3B
| $11M | 0.05% |
86,699
-68,486
| -44% | -$8.61M |
|
225
AGCO
AGCO
$8.78B
| $10.9M | 0.05% |
152,849
-633
| -0.4% | -$45.2K |
|
Similar funds
DAM
VanEck Associates's Q4 2017 Portfolio in Review
As of Q4 2017, VanEck Associates held 742 positions worth $20.3B, up 3.6% from $19.6B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
VanEck Associates's Q4 2017 filing shows 18 new, 309 increased, 385 reduced and 26 closed positions. Its largest new stake was Core Natural Resources Inc: 727,364 shares worth $28.7M. The largest sale was Newmont, an estimated $112M.
By sector, the portfolio is most concentrated in Materials at 50% of assets, down from 52% a quarter earlier, followed by Energy and Healthcare.
- VanEck Associates's largest Q4 2017 buy was Core Natural Resources Inc: 727,364 shares worth $28.7M.
- VanEck Associates added most to SLB Ltd in Q4 2017, an estimated $82.6M increase.
- VanEck Associates's biggest Q4 2017 reduction was Newmont, cutting an estimated $112M.
- VanEck Associates fully exited Richmont Mines Inc. in Q4 2017, selling an estimated $38.2M.
- VanEck Associates's ten largest holdings make up 25% of its $20.3B portfolio in Q4 2017.
- VanEck Associates opened 18 new positions and closed 26 in Q4 2017.
- VanEck Associates's portfolio value rose 3.6% quarter-over-quarter to $20.3B.
Based on VanEck Associates's 13F filing for Q4 2017, filed 12 Feb 2018.